SCHEDULE 13G/A: AWM Investment Company Discloses 7.5% Passive Stake in Oncocyte Corp.

AWM Investment Company, Inc. has filed an amended Schedule 13G, disclosing a 7.5% passive ownership stake in Oncocyte Corp. as of December 31, 2024.

Summary

• AWM Investment Company, Inc. (AWM) filed an Amendment No. 2 to Schedule 13G, indicating its beneficial ownership in Oncocyte Corp.
• As of December 31, 2024, AWM beneficially owns an aggregate of 1,306,309 shares of Oncocyte Corp. Common Stock.
• This ownership represents 7.5% of the outstanding class of Oncocyte Corp. Common Stock.
• AWM, acting as the investment adviser to Special Situations Cayman Fund, L.P., Special Situations Fund III QP, L.P., Special Situations Private Equity Fund, L.P., and Special Situations Life Sciences Fund, L.P. (the Funds), holds sole voting and dispositive power over these shares.
• The beneficial ownership includes common stock, pre-funded warrants, and warrants held by the various funds.
• Specifically, the holdings include 179,725 shares, 77,434 Pre-Funded Warrants, and 656,661 Warrants (to purchase 32,833 shares) for CAYMAN; 596,079 shares, 265,454 Pre-Funded Warrants, and 2,345,216 Warrants (to purchase 117,261 shares) for SSFQP; 375,234 Warrants (to purchase 18,762 shares) for SSPE; and 375,234 Warrants (to purchase 18,762 shares) for SSLS.
• The warrants are subject to a beneficial ownership limitation, meaning they can only be exercised to the extent that the total number of common shares then beneficially owned does not exceed 9.99% of the outstanding shares.

Sentiment

Score: 7

Explanation: The filing indicates significant institutional investment in Oncocyte Corp., which is generally viewed positively as a vote of confidence, although it is a passive stake and does not imply active engagement or control.

Positives

• The disclosure of a significant passive stake by AWM Investment Company, Inc., a professional investment adviser, indicates institutional interest and potential confidence in Oncocyte Corp.'s long-term prospects.
• The investment is diversified across multiple Special Situations Funds advised by AWM, suggesting a broader institutional commitment.

Negatives

• The filing explicitly states that AWM's investment is passive, meaning they do not intend to influence or change control of Oncocyte Corp., which limits potential activist engagement.

Risks

• Warrants held by AWM's funds are subject to a beneficial ownership limitation, restricting their exercise if total ownership exceeds 9.99% of outstanding shares, which could impact the full realization of potential shareholdings.

Future Outlook

The document does not provide forward-looking statements or guidance from Oncocyte Corp. It solely details a passive investment stake by AWM Investment Company, Inc. and its advised funds.

Industry Context

This filing is a routine disclosure of a significant passive ownership stake by an institutional investor. It does not provide specific insights into broader industry trends or competitive landscape for Oncocyte Corp.

Stakeholder Impact

• Shareholders: Increased institutional ownership may provide a degree of stability and confidence in the company's stock, as it signals a professional investor's belief in the company's value.

Key Dates

Recommendation

Keywords

Oncocyte Corp, AWM Investment Company, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Warrants, Passive Investment, Institutional Investor